AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.

Authors

Lili Wang
Peter Bell
Hiroki Morizono, George Washington University
Zhenning He
Elena Pumbo
Hongwei Yu
John White
Mark L Batshaw, George Washington UniversityFollow
James M Wilson

Document Type

Journal Article

Publication Date

4-1-2017

Journal

Molecular Genetics and Metabolism

Volume

120

Issue

4

Inclusive Pages

299-305

DOI

10.1016/j.ymgme.2017.02.011

Keywords

Aging; Animals; Dependovirus; Disease Models, Animal; Female; Genetic Therapy; Genetic Vectors; Humans; Liver Cirrhosis; Male; Mice; Mice, Knockout; Ornithine Carbamoyltransferase; Ornithine Carbamoyltransferase Deficiency Disease; Treatment Outcome

APA Citation

Wang, L., Bell, P., Morizono, H., He, Z., Pumbo, E., Yu, H., White, J., Batshaw, M., & Wilson, J. (2017). AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.. Molecular Genetics and Metabolism, 120 (4). http://dx.doi.org/10.1016/j.ymgme.2017.02.011

Peer Reviewed

1